Guillain-Barre syndrome following the first dose of SARS-CoV-2 vaccine, Oxford/AstraZeneca (ChAdOx1) / Síndrome de Guillain-Barre após a primeira dose da vacina contra a SRA-CoV-2, Oxford/AstraZeneca (ChAdOx1)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.